Although the introduction of HER-2 inhibitors, including trastuzumab, pertuzumab and lapatinib in the chemotherapy regimen of HER-2 positive invasive breast cancer, has dramatically improved the remission and mortality rate in both early and metastatic settings, cancer-related cardiac dysfunction (CTRCD) due to this targeted therapy has been a concern, especially in combined anthracycline and trastuzumab therapy (1). The gene discussed is ERBB2; the disease is cancer.